What are the biopharmaceutical equipment?
Biopharmaceutical laboratories usually use shaker, bioreactor, fermentor, incubator, biochemical incubator, carbon dioxide incubator, autoclave, circulating water cooler, air compressor, cell crusher, high-pressure homogenizer, freeze dryer, spray drier, centrifugal concentrator, biochemical analyzer, etc.
Analysis of biopharmaceutical industry
Bio-pharmacy is a method to produce drugs by using organisms, such as producing human antibodies by using transgenic corn and expressing human α 1 antitrypsin in transgenic bovine mammary glands. The biopharmaceutical industry has broad prospects. Half of the drugs in the world are biosynthetic, which will be widely used to treat cancer, AIDS, coronary heart disease, anemia, dysplasia, diabetes and other diseases. Antibiotics used in medicine mostly come from microorganisms, such as erythromycin and clindamycin, penicillin for injection, streptomycin and gentamicin. The number of people engaged in research, development, production and management of biotechnology industry in China is only 1/4 of that in the United States. The serious shortage of talents engaged in research and development of biomedical products has become a bottleneck restricting the development of biomedical industry in China.
The development of domestic biopharmaceutical industry is characterized by small scale, low concentration and rapid growth. Although the sales volume of China's biopharmaceutical industry has increased substantially, it is only close to Amgen, an American biochemical company. The annual sales of five listed companies, Hualan Bio, Tiantan Bio, Ke Hua Bio, Shuanglu Pharmaceutical and Daan Gene, only account for about 4% of the market share. The capacity structure of biopharmaceutical enterprises in China is unbalanced, the capacity of high-end drugs is insufficient, and the overcapacity of low-end drugs appears. For example, more than half of China's vaccine production is used to prevent common diseases such as polio and measles, and there is no cutting-edge cancer and AIDS vaccine. At present, the independent research and development ability of biopharmaceutical enterprises in China is relatively weak, mainly generic drugs and raw materials, and their competitiveness is poor. Only about 5% of biopharmaceuticals that have been approved for marketing in China are original drugs, and most of them are generic drugs. Only a few biopharmaceutical companies in the domestic biopharmaceutical industry have R&D investment close to the international level, and most biopharmaceutical companies have less R&D investment.
Prospect analysis of biopharmaceuticals
development prospect
As a high-tech technology, biopharmaceutical technology was born in the early 1970s, accompanied by the invention and application of DNA recombination technology and lymphocyte hybridoma technology. In the past 30 years, the rapid development of biopharmaceutical technology has opened up broad prospects for the development of medical industry and pharmaceutical industry, and greatly improved people's lives. Therefore, countries all over the world have identified biopharmaceuticals as the key technologies and emerging industries for scientific and technological development in the 2 1 century.
The particularity of biopharmaceuticals is that biopharmaceuticals have become one of the fastest growing industries at home and abroad. The century of 265,438+0 is the century of biotechnology, and biopharmaceuticals have become the focus of testing China's high-tech development.
In the shadow of the global financial crisis, the pharmaceutical market in emerging countries stands out. As one of the BRIC countries, China's biopharmaceutical market is particularly bright. The National Development and Reform Commission allocated an additional 442 million yuan from the central government to support special projects such as high-tech industrialization of biomedicine, biological breeding and biomedical engineering, and the construction of public service conditions in the national bio-industrial base. This move has injected new impetus into the future development of biopharmaceuticals.
Although after years of development, China's biomedical industry has a good foundation, compared with the biomedical industry in advanced countries in the world, there are still many gaps in China's biomedical industry. The development of biomedical industry in China will be a difficult road from scientific research to industrialization. Governments at all levels, from national to local, have continuously increased their support for the development of biomedical industry. By 2020, China will basically realize industrialization and establish a sound socialist market economic system and a more dynamic and open economic system. At the same time, the social security system is relatively sound, and a relatively perfect modern medical and health system will be formed. These two factors will create a huge market space and a good development environment for biomedical industry.
future
Generally speaking, the future of biopharmaceutical industry in China is full of hope and promising. Looking ahead, the biopharmaceutical industry in China will continue to grow. In the future, China's biological and biochemical products industry will still show a rapid development trend.
Salary level: Because medical engineers cover many fields, the employer's situation is different from everyone's education and ability, so the salary flexibility of this profession is great. The average college graduate's monthly salary is about 3000 yuan.
Career prospects: comprehensive talents, which integrates biology, medicine and engineering technology, has a good prospect. Such talents need to have two skills: one is the research and development of new products, and the other is the operation of instruments. Biomedical engineering, biotechnology, bioinformatics, medical and health departments and related units have a strong demand for such talents. ......
Occupational characteristics
Professional Prospect Biotechnology drugs have been widely used to treat cancer, AIDS, anemia, dysplasia, diabetes, heart failure, hemophilia, cystic fibrosis and some rare genetic diseases. Many large pharmaceutical companies are facing the situation that a large number of patents are about to expire, and their product reserves are very insufficient, so they have to look for new drugs from life science companies. New drug discovery technology makes it cheaper, faster and more accurate to find drug targets for special diseases.
Career prospects
China is a populous country in the world. The number of people engaged in research and development in biotechnology industry is 1.7 million, and the number of people engaged in production and operation is 0.9 million, which is only equivalent to 1/4 of the number of people in biotechnology industry in the United States. The serious shortage of talents engaged in research and development of biomedical products has become a bottleneck restricting the development of biomedical industry in China.
It can be seen that the development of China's biomedical industry urgently needs a large number of senior medical talents.